Therapy Detail

Therapy Name ST-162 + unspecified PD-1 antibody
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
ST-162 ST-162 is a dual kinase inhibitor of MAPK and PI3K signaling, which may result in decreased phosphorylation of Akt and Erk and subsequent tumor regression (PMID: 28775144).
unspecified PD-1 antibody Experimental PD-1 antibody PD-L1/PD-1 antibody 50
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colorectal cancer predicted - sensitive ST-162 + unspecified PD-1 antibody Preclinical Actionable In a preclinical study, ST-162 therapy combined with an anti-PD-1 antibody resulted in greater tumor growth inhibition than treatment with either agent alone in a colorectal cancer mouse model (PMID: 28775144). 28775144
Clinical Trial Phase Therapies Title Recruitment Status